BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Company update

MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company’s common shares,

Related news

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

TERNTerns Pharmaceuticals2026-04-02 20:05 EST

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

NAMSNewAmsterdam Pharma2026-08-06 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALGSAligos Therapeutics2026-04-24 12:00 EST

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MLYSMineralys Therapeutics2026-07-27 20:01 EST

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SGMTSagimet Biosciences2026-06-23 00:49 EST

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SGMTSagimet Biosciences2026-04-06 11:00 EST

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LXRXLexicon Pharmaceuticals2026-07-27 12:30 EST

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

RYTMRhythm Pharmaceuticals2026-05-01 10:55 EST

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm. Atrial Fibrillation...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-07-03 01:30 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-05-06 12:00 EST

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

Stock data

Close
1.18 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States